Leveraging Rules and Alerts to Improve Patient Safety and Clinical Pharmacy Services

Size: px
Start display at page:

Download "Leveraging Rules and Alerts to Improve Patient Safety and Clinical Pharmacy Services"

Transcription

1 Objectives Leveraging Rules and Alerts to Improve Patient Safety and Clinical Pharmacy Services Sonali Muzumdar Pharm.D., CPHIMS Informatics Pharmacist Mercy Hospital and Medical Center Comprehensive Pharmacy Services Describe a method to assist pharmacist identification of changing renal function over time for patients on renally adjusted medications Identify a method to improve patient safety by preventing medication errors associated with weight changes List pharmacy clinical services that can be improved by use of rules and alerts 1 2 Audience Poll Mercy Hospital & Medical Center Chicago, Illinois How many sites have CPOE? 3 4 Mercy Overview History and Mission MAPS Timeline Applications Healthcare Information Management & Systems Society Stage 6 Hospital Recognition The Leapfrog Group Quick Facts 479 Licensed Beds 286 Staffed Beds 16,353 Annual Inpatients 14 Offsite locations 252,630 Outpatient Visits 56,172 ED Visits 1,503 FTE s 100 Interns and Residents 5 1

2 EHR Applications (Cernerize) PowerChart E-prescribe Power Note PowerPlans PowerOrders CareNet SurgiNet / Anesthesia RadNet ProVision Web I-Net NHIQM Dashboard PharmNet FirstNet APACHE CareAware CareMobile Discern Expert/Explorer BMDI/Open Port CPOE ProFile - HIM Foreign System Interfaces Knowledge Catalog M Pages Pharmacy Team 15 Clinical Pharmacists 6 Clinical Specialists 2 Internal Medicine 2 Emergency Medicine 1 Ambulatory Care 1 Critical Care 2 Pharmacy Practice Residents 1 Informatics Pharmacist (0.6 FTE) DOP, ADOP, Clinical Manager 20 FTE pharmacy technicians 7 8 Pharmacy Clinical Services Renal dosing Automatic IV-PO conversion Anticoagulation management service Pharmacokinetic monitoring Inhaler training Anticoagulant counseling Medication profile review JCAHO Recommendations Safety alerts should help clinicians determine urgency and relevancy. Review skipped or rejected alerts as important insight into clinical practice. Review appopriate documentation to determine which which alerts need to be a hard stop JCAHO Recommendations After implementation, continually reassess and enhance safety effectiveness and error-detection capability, including the use of error tracking tools and the evaluation of near-miss events. Maximize the potential of the technology in order to maximize the safety benefits. Outline Mercy Hospital and Medical Center Overview Renal Rule Weight Change Anticoagulant Counseling Anticoagulant alerts

3 Renal Dosing Gap Identified History Adjust medications for impaired renal function at order verification Built in stop dates Creatinine clearance changes over time McCoy et al Population: adult inpatients with acute kidney injury Intervention: interruptive alert to modify medication therapy Conclusion: Increased rate and timeliness of modification or discontinuation of targeted orders Medications readjusted at time of renewal verification or medication profile review McCoy et al. Am J Kidney Dis : Renally Adjusted Medications RIFLE Criteria Acyclovir, Valacyclovir Alendronate Allopurinol Amphoteracin Beta-lactams Bivalirudin Ciprofloxacin, Levofloxacin Colchicine Colistin Dabigatran Enoxaparin, Fondaparinux Famciclovir, Ganciclovir Famotidine, Ranitidine Fluconazole, Voriconazole Hydroxyurea Ketorolac Levetiracetam Lithium Memantine Metformin Methylnaltrexone NRTIs Oprelvekin Quinidine Rifabutin Sotalol Spironolactone Tetracycline SMX-TMP Zoledronic acid Bellomo et al. Crit Care :R Pilot Testing Design of Renal Rule Change in Serum Creatinine Time Period (hours) Resulted in a Meaningful Medication Review 50% 24 1/5 (20%) 30% 24 6/15 (40%) 30% (lower limit of 0.8) 24 5/10 (50%) 30% (lower limit of 0.8) 72 10/15 (67%) Age >= 18 yrs Patient has an active order for a renally excreted medication Serum creatinine >= 0.8 mg/dl Change in serum creatinine is at least 30% Subsequent serum creatinine has changed Patient does not have any hemodialysis orders Change has occurred within a 72 hour period Pharmacy Renal Evaluation order is fired Task fires to the pharmacy task list

4 Real time testing Have the alert go to your Review rules prior to turning them on for the department Review alert fatigue Testing/Building Rules Evaluate encounter specificity Evaluate the medication order type Task List Example Interventions RENAL INTERVENTIONS % Increase Q12012 Q12013 Q Quality Improvement Data Reported quarterly to Medication and Nutrition Committee Data for one week s audit Task fired 49 times 17/49 had medications that needed adjustment Ongoing Changes Utilize Cockcroft-Gault Creatinine Clearance (CrCl) Medication specific CrCl cutoffs

5 Outline Mercy Hospital and Medical Center Overview Renal Rule Task Weight Change Task Warfarin Counseling Task Senior ED Task Audience Poll Who has a weight problem? ISMP Best Practice for 2014 Measure and express patient weights in metric units only. Ensure that scales used for weighing patients are set and measure only in metric units. Numerous medication errors have been reported Importance of a Correct Weight Affects drug dosing Drugs dosed in mg/kg, mcg/kg/min Drugs dosed based on BMI & BSA Cockcroft-Gault formula Dietary requirements Monitoring heart failure patients Documentation Errors Pounds instead of kilograms Typographical errors (105 cm vs 150 cm) Height & Weight numbers are transposed Estimated weight is never updated Another patient s weight entered in the system Medication Error Example Order: panitumumab IV every 3 weeks Usual dose: 6 mg/kg every 2 weeks Clinical trial dose: 9 mg/kg every 3 weeks Height (cm) was entered as the weight and the weight (kg) was entered as the height Result: the patient received about 650 mg more panitumumab than intended for the first dose of therapy ISMP newsletter. August ISMP newsletter. August

6 Height & Weight Documentation Documenting Weight Based Drips Clinical Weight automatically defaults for weight based dosing Height & Weight Documentation Medication Safety Committee Review In the ED Estimated Weight & Clinical Weight On the floor Measured Weight is performed and The Clinical Weight is updated by the floor nurse/cna to match the Measured Weight Current Height/Weight form does not alert the user if there is a weight change from previous documentation Potential for error exists during documentation Pharmacy should be notified if there is a significant weight change Design of Weight Task Rule Future Height & Weight Documentation Clinical Weight Subsequent Measured Weight Task fires if there is more than a 15% change In the ED Estimated Weight & Clinical Weight On the floor Measured Weight is performed and Clinical Weight can only be updated by pharmacy

7 Pharmacist Clinical Process Task fires Pharmacist communicates with the RN to reweigh the patient Update clinical weight Review patient profile Correct dose and/or interval Outcomes of the Weight Task Old incorrect weight: 120 kg New correct and verified weight: 100 kg Heparin infusion and boluses 80 units/kg bolus ( units) 40 units/kg bolus ( units) Rate 18 units/kg/hr to 21.6 units/kg/hr (ml/hr remains unchanged) Enoxaparin 120 mg Q12H to 100 mg Q12H Cefepime 2 gram Q8H to 2 gram Q12H Monthly Pharmacy Weight Tasks Weight Task Changes February 2013 to March 2014 Pharmacy Weight Tasks Changed task to look at a 15% weight change from 5kg weight change Averaging 15 tasks per week Significant pharmacist time Correction did not occur quickly Alert for RN/CNA built Alert for nurse and cna Outline Mercy Hospital and Medical Center Overview Renal Rule Task Weight Change Task Anticoagulation Counseling Task Anticoagulant Alerts

8 Jan-12 Feb-12 Mar-12 Apr-12 May-12 Jun-12 Jul-12 Aug-12 Sep-12 Oct-12 Nov-12 Dec-12 Jan-13 Feb-13 Mar-13 Apr-13 May-13 Jun-13 Jul-13 Aug-13 Sep-13 Oct-13 Nov-13 Dec-13 5/2/2014 Warfarin Counseling Goals Department goal 50% of inpatients receive warfarin counseling Assist in documentation National Hospital Inpatient Quality measures VTE-5: Venous thromboembolism warfarin therapy discharge instructions Compliance Dietary advice Follow-up monitoring Potential for adverse drug reactions and interactions Warfarin Counseling Task Process Warfarin ordered Rule fires a placeholder pharmacy order Patient on Warfarin Patient on Warfarin orderable fires a Pharmacy Warfarin Counseling task Pharmacist charts on the task, the quality measure form is attached Quality Measure Documentation Improvement in Patient Counseling Counseling task fired 9/2012 % Patients counseled from Jan 2012-Dec 2013 Goal = 50% Limitations of the task list Task list is not front & center for the pharmacists Keeping up with the task list Duplicate tasks Outline Mercy Hospital and Medical Center Overview Renal Rule Task Weight Change Task Warfarin Counseling Task Anticoagulation safety

9 Audience Poll Black Box Warning Does your EHR alert you when your patient has received an epidural morphine injection and enoxaparin is ordered? WARNING: SPINAL/EPIDURAL HEMATOMA Epidural or spinal hematomas may occur in patients who are anticoagulated with low molecular weight heparins (LMWH) or heparinoids and are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include: Use of indwelling epidural catheters Concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants A history of traumatic or repeated epidural or spinal punctures A history of spinal deformity or spinal surgery Anticoagulants and Spinal Anesthesia Increased risk of spinal hematoma when used in conjunction with epidural/spinal procedures Anticoagulants and Epidurals Drug Anticoagulant on profile Heparin IV May remove catheter 2-4 hrs after last heparin dose Epidural on profile May heparinize 1 hr after neuraxial technique Each drug has it s own recommendation for timing Timing for when to administer the anticoagulant and when to administer the medication with epidural/intrathecal route. Clopidogrel/Ticagrelor Direct thrombin inhibitors discontinue 7 days prior to neuraxial blockade -Insufficient information: recommend against the performance of neuraxial techniques (Grade 2C) -Needle placement 8-10 hrs after dose (GSAICM) N/A Delay subsequent doses 2-4 hrs after needle placement 52 Vanderbilt Clinical Decision Support Alert at procedural time if there is an existing anticoagulant Warning when initiating an anticoagulant and patient has an existing epidural Events decreased from 26 to 11 for a 3 month time frame. Anticoagulant-Epidural Alert Need due to lack of notification in our EHR Improve our generic epidural alert Discussed with anesthesiologists Guidelines developed Referenced ASRA, GSAICM, ACCP 2 Alerts built per anticoagulant Prior to catheter administration After catheter removal Gupta RK et al. Using An Electronic Clinical Decision Support System to Reduce the Risk of Epidural Hematoma. Am J Ther Oct 19. [Epub ahead of print]

10 Anticoagulant-Epidural Warning after VTE-1: Venous Thromboprophylaxis Assesses the number of patients who received VTE prophylaxis or have documentation why no VTE prophylaxis was given Patients should receive prophylaxis within first 2 days of hospital admission VTE Prophylaxis Increase in VTE prophylaxis orders Order sets Core measures Patients with a therapeutic INR Guidance/Legislation/EHRIncentivePrograms/Downloads/2014_CQM_EH_FinalRule.pdf Elevated INR Alert Quality Improvement Data Alert fires from 3-11/month Reported quarterly to Medication & Nutrition Committee 15/19 (79%) appropriate interventions Modify alert so an over-ride reason is required Alerts fired Non-med induced INR elevation Medication induced INR elevation Pharmacist interventions Bypassed alerts/ missed intervention Oct Nov Dec

11 Conclusions An interruputive renal task is beneficial to clinical pharmacy services Correction of weight documentation errors can prevent dosing errors Anticoagulation safety can be improved with specific drugdrug and drug-lab alerts Review Questions A combination of rules and a task list can help improve a pharmacy s renal dosing program. True or False TRUE Review Questions Which of the following can cause weight documentation errors? a. Documenting in pounds vs kg b. Typographical errors c. Another patient s weight d. Height and Weight transposed e. Estimated weight is never updated f. All of the above ALL OF THE ABOVE Review Questions There is an increased risk of spinal bleeding when some anticoagulants are administered to patients that have received an epidural/intrathecal medication. TRUE OR FALSE TRUE

Venous Thromboembolism National Hospital Inpatient Quality Measures

Venous Thromboembolism National Hospital Inpatient Quality Measures Venous Thromboembolism National Hospital Inpatient Quality Measures Presentation Overview Review venous thromboembolism as a new mandatory measure set Outline measures with exclusions and documentation

More information

Ensuring Safety of Anticoagulation Therapy

Ensuring Safety of Anticoagulation Therapy Ensuring Safety of Anticoagulation Therapy Abha Agrawal, MD, FACP Chief Medical Officer Kings County Hospital Clinical Associate Dean SUNY Downstate College of Medicine Brooklyn, NY NYACP Webinar April

More information

2.5 Other Hematology Consult:

2.5 Other Hematology Consult: The Warfarin Order Sheet has been approved by the P & T committee to be implemented by pharmacists. These orders are not used to treat patients with serious hemorrhagic complications. WARFARIN TARGET INR

More information

Low Risk Non-surgical medicine patients without any Mechanical prophylaxis

Low Risk Non-surgical medicine patients without any Mechanical prophylaxis ADULT VENOUS THROMBOEMBOLISM (VTE) PROPHYLAXIS GUIDELINE This document is intended as a guideline only and should not replace sound clinical judgment. I. VTE risk assessment and selection of prophylaxis:

More information

Dr. Steve Ligertwood Dr. Roderick Tukker Dr. David Wilton

Dr. Steve Ligertwood Dr. Roderick Tukker Dr. David Wilton Dr. Steve Ligertwood Hospitalist Royal Columbian Hospital Regional Department Head-Hospitalist for Fraser Health Authority Project Lead BC Hospitalist VTE Collaborative Clinical Instructor, UBC School

More information

Heparin Drip. Ordering

Heparin Drip. Ordering Heparin Drip Ordering Nurse entering of Heparin drip orders for physicians should only occur in situations when it is not feasible for the physician to enter orders directly Select the Heparin IV Drip

More information

Appendix IV - Prescribing Guidance for Apixaban

Appendix IV - Prescribing Guidance for Apixaban Appendix IV - Prescribing Guidance for Apixaban Patient Factors Dose of Apixaban If your patient has any of the following MAJOR risk factors: Hypersensitivity to the active substance or to any of the excipients

More information

3/19/2012. What is the indication for anticoagulation? Has the patient previously been on warfarin? If so, what % of the time was the INR therapeutic?

3/19/2012. What is the indication for anticoagulation? Has the patient previously been on warfarin? If so, what % of the time was the INR therapeutic? Abigail E. Miller, PharmD, BCPS Clinical Specialist, Cardiology University of North Carolina Hospitals I have no personal financial relationships with the manufacturers of the products to disclose. Boehringer

More information

Utilizing Automated Adverse Event Detection

Utilizing Automated Adverse Event Detection Utilizing Automated Adverse Event Detection David C Stockwell, MD, MBA Executive Director of Improvement Science Medical Director of Patient Safety and Pediatric ICU Children s National Medical Center

More information

Implementation of an Interprofessional Team to Prevent Inpatient Hypoglycemic Events. September 13, 2016

Implementation of an Interprofessional Team to Prevent Inpatient Hypoglycemic Events. September 13, 2016 Implementation of an Interprofessional Team to Prevent Inpatient Hypoglycemic Events September 13, 2016 St Joseph s Health Fast Facts Founded 1869 by Sisters of St. Francis Patient Volumes (2014) Inpatient

More information

WMC PHARMACY ANTICOAGULATION PROTOCOL Current Revision: July 2017 GENERAL ORDER PROCESSING AND MANAGEMENT

WMC PHARMACY ANTICOAGULATION PROTOCOL Current Revision: July 2017 GENERAL ORDER PROCESSING AND MANAGEMENT WMC PHARMACY ANTICOAGULATION PROTOCOL Current Revision: July 2017 GENERAL ORDER PROCESSING AND MANAGEMENT - Entering orders for anticoagulation in Cerner Providers will enter individual orders (oneoffs)

More information

Venous Thromboembolism Prophylaxis

Venous Thromboembolism Prophylaxis Approved by: Venous Thromboembolism Prophylaxis Vice President and Chief Medical Officer; and Vice President and Chief Operating Officer Corporate Policy & Procedures Manual Number: Date Approved January

More information

Factor Xa Inhibition in the Management of Venous Thromboembolism: Important Safety Information. Important Safety Information (cont d)

Factor Xa Inhibition in the Management of Venous Thromboembolism: Important Safety Information. Important Safety Information (cont d) Factor Xa Inhibition in the Management of Venous Thromboembolism: The Role of Fondaparinux WARNING: SPINAL/EPIDURAL HEMATOMAS Epidural or spinal hematomas may occur in patients who are anticoagulated with

More information

Reducing Readmissions and Improving Outcomes at OhioHealth Mansfield Hospital:

Reducing Readmissions and Improving Outcomes at OhioHealth Mansfield Hospital: Reducing Readmissions and Improving Outcomes at OhioHealth Mansfield Hospital: Eugenio H. Zabaleta, Ph.D. Clinical Chemist OhioHealth Mansfield Hospital Reducing Readmissions and Improving Outcomes at

More information

Collaborating to Implement Evidence-Based Medicine Tools. The St. John Sepsis Agent and the Interdisciplinary Sepsis Advisor

Collaborating to Implement Evidence-Based Medicine Tools. The St. John Sepsis Agent and the Interdisciplinary Sepsis Advisor Collaborating to Implement Evidence-Based Medicine Tools The St. John Sepsis Agent and the Interdisciplinary Sepsis Advisor Learning Objectives Describe an effective implementation strategy for clinical

More information

What s new with DOACs? Defining place in therapy for edoxaban &

What s new with DOACs? Defining place in therapy for edoxaban & What s new with DOACs? Defining place in therapy for edoxaban & Use of DOACs in cardioversion Caitlin M. Gibson, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy University of North Texas

More information

CCHHSQualityDashboard-DRAFT

CCHHSQualityDashboard-DRAFT CCHHSQualityDashboard-DRAFT9..8 Falswith Injury Pressure Injury(Stage I&IV) Aug-7 Nov-7 Feb-8 May-8 Aug-8 Aug-7 Nov-7 Feb-8 May-8 Aug-8 0 4 9 8 5 5 6 5 HospitalAcquiredConditions 07Q 07Q4 08Q 08Q 0.00

More information

2/9/2016. A Multi-Disciplinary Program to Decrease the Rate of Preventable Harm from Medication Events. Objectives:

2/9/2016. A Multi-Disciplinary Program to Decrease the Rate of Preventable Harm from Medication Events. Objectives: A Multi-Disciplinary Program to Decrease the Rate of Preventable Harm from Medication Events Michigan Pharmacist Association February 28, 2016 Steven Johnson, Pharm.D. Regional Clinical Director Gay Alcenius,

More information

Admit date (YYYY/MM/DD): Cardiologist On-Call: Diagnosis: Lab Tests. CBC, Electrolytes, Urea, Creatinine, Glucose, INR, PTT, Urinalysis

Admit date (YYYY/MM/DD): Cardiologist On-Call: Diagnosis: Lab Tests. CBC, Electrolytes, Urea, Creatinine, Glucose, INR, PTT, Urinalysis of nurse 1. Admit under ward Attending Physician: Dr. Admit date (YYYY/MM/DD): Cardiologist On-Call: Diagnosis: Lab Tests 2. On admission (if not already performed in Emergency Department or in Coronary

More information

New Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY

New Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY New Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY Fact VTE is deadly! It nibbles after it bites! The 30-day mortality rates for first-time DVT or

More information

THROMBOPROPHYLAXIS: NON-ORTHOPEDIC SURGERY

THROMBOPROPHYLAXIS: NON-ORTHOPEDIC SURGERY THROMBOPROPHYLAXIS: NON-ORTHOPEDIC SURGERY OBJECTIVE: To outline a practical approach for the prevention of venous thromboembolism (VTE) in patients undergoing non-orthopedic surgery. BACKGROUND: VTE is

More information

a. A pharmacist may order a baseline SCr per protocol

a. A pharmacist may order a baseline SCr per protocol UNITYPOINT HEALTH - MARSHALLTOWN Marshalltown, Iowa PHARMACY POLICY AND PROCEDURE Subject: Anticoagulant Therapy Per Practice Protocol (Formerly Anticoagulant therapy #NPSG.03.05.01) Inpatient Warfarin

More information

AUDIT REPORT. Salisbury District Hospital. Odstock Road. Salisbury. Wiltshire. February Page 1 of 20

AUDIT REPORT. Salisbury District Hospital. Odstock Road. Salisbury. Wiltshire. February Page 1 of 20 AUDIT REPORT Prescribing of Treatment Dose Dalteparin Based on Patient Weight and Renal Function, and the Recording of these Parameters on the Drug Chart. Author : Location : Janeen Linsley Salisbury District

More information

Venous Thromboembolism (VTE) Prevention

Venous Thromboembolism (VTE) Prevention Venous Thromboembolism (VTE) Prevention 7 VTE Risk Assessment: General Patient Population Assess VTE risk at admission, post-op, and transfer See page 2 for VTE risk assessment among Obstetrical (OB) patients

More information

Xarelto (rivaroxaban) Prescriber Guide

Xarelto (rivaroxaban) Prescriber Guide Xarelto (rivaroxaban) Prescriber Guide October 2018 PP-XAR-IE-0031 Contents Patient Alert Card 4 Dosing Recommendations 4 Stroke prevention in adult patients with non-valvular atrial fibrillation 4 Patients

More information

Quality Improvement Updates Foley Discontinuation Protocol Surgical Care Improvement Project

Quality Improvement Updates Foley Discontinuation Protocol Surgical Care Improvement Project Quality Improvement Updates Foley Discontinuation Protocol Surgical Care Improvement Project Barbara J Martin, RN, MBA Quality Consultant, Center for Clinical Improvement Indwelling Urinary Catheters Insertion,

More information

NOTE: The first appearance of terms in bold in the body of this document (except titles) are defined terms please refer to the Definitions section.

NOTE: The first appearance of terms in bold in the body of this document (except titles) are defined terms please refer to the Definitions section. TITLE VENOUS THROMBOEMBOLISM PROPHYLAXIS SCOPE Provincial Acute and Sub-Acute Care Facilities APPROVAL AUTHORITY Alberta Health Services Executive Committee SPONSOR Vice President, Quality and Chief Medical

More information

Venothromboembolism prophylaxis: Trauma and Orthopaedics Clinical guideline, V2

Venothromboembolism prophylaxis: Trauma and Orthopaedics Clinical guideline, V2 Clinical Guideline Venothromboembolism prophylaxis: Trauma and Orthopaedics 11/11/11 TEMPORARY GUIDANCE There is no prophylactic tinzaparin available in the Trust currently. Please substitute enoxaparin

More information

Anticoagulation

Anticoagulation 041218 Anticoagulation 2018 About This Presentation Strategic Vectors: Clinical Outcomes Patient Safety Physician Engagement Team: Dr. Joseph DeCristofaro Karin Ganetis, RN Dr. Stephen A. Vitkun Dr. Lisa

More information

Outpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2015

Outpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2015 Outpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2015 General Principles: There is compelling data in the medical literature to support

More information

Venous Thromboembolism. Prevention

Venous Thromboembolism. Prevention Venous Thromboembolism Prevention August 2010 Venous Thromboembloism Prevention 1 1 Expected Practice Assess all patients upon admission to the ICU for risk factors of venous thromboembolism (VTE) and

More information

Hot Topics: Transitions of Care

Hot Topics: Transitions of Care Our quarterly newsletter is a great way to stay up-to-date on emerging clinical information, medication safety issues, and Larkin s Hospital medication policies and procedures. Hot Topics: Transitions

More information

10/8/2012. Disclosures. Making Sense of AT9: Review of the 2012 ACCP Antithrombotic Guidelines. Goals and Objectives. Outline

10/8/2012. Disclosures. Making Sense of AT9: Review of the 2012 ACCP Antithrombotic Guidelines. Goals and Objectives. Outline Disclosures Making Sense of AT9: Review of the 2012 ACCP Antithrombotic Guidelines No relevant conflicts of interest related to the topic presented. Cyndy Brocklebank, PharmD, CDE Chronic Disease Management

More information

DEEP VEIN THROMBOSIS (DVT): TREATMENT

DEEP VEIN THROMBOSIS (DVT): TREATMENT DEEP VEIN THROMBOSIS (DVT): TREATMENT OBJECTIVE: To provide an evidence-based approach to treatment of patients presenting with deep vein thrombosis (DVT). BACKGROUND: An estimated 45,000 patients in Canada

More information

Session #206, March 8, 2018 Susan J. Kressly, MD, FAAP, Kressly Pediatrics Dr. Jacques Orces, D.O., Nicklaus Children s Hospital

Session #206, March 8, 2018 Susan J. Kressly, MD, FAAP, Kressly Pediatrics Dr. Jacques Orces, D.O., Nicklaus Children s Hospital Improving Preventative Care in Pediatrics through Health and Technology: A Davies Story Session #206, March 8, 2018 Susan J. Kressly, MD, FAAP, Kressly Pediatrics Dr. Jacques Orces, D.O., Nicklaus Children

More information

Pathology Service User Guide Haematology

Pathology Service User Guide Haematology Pathology Service User Guide Haematology St Richard s This section of the Pathology Service User Guide includes: Anticoagulant Therapy Information about the Anticoagulant Clinic Low Molecular Weight Heparin

More information

Monitoring Protocol for Clozapine-induced Myocarditis. Copyright 2017, CAMH

Monitoring Protocol for Clozapine-induced Myocarditis. Copyright 2017, CAMH 1 Monitoring Protocol for Clozapine-induced Myocarditis 1 Agenda Problem Identification / Identification Importance / Importance Baseline Workflow Baseline Workflow Baseline Data Baseline Data Objectives

More information

Funding: The ASRA Consensus Conference was funded by unrestricted educational grants from: Pharmacia & Upjohn Company and Aventis Pharmaceuticals

Funding: The ASRA Consensus Conference was funded by unrestricted educational grants from: Pharmacia & Upjohn Company and Aventis Pharmaceuticals Regional Anesthesia in the Anticoagulated Patient - Defining the Risks Published by the American Society of Regional Anesthesia and Pain Medicine This document has been developed by a Consensus Conference

More information

Intervention Study 2016 West ISD. Gillian Ritchie Clinical Pharmacist

Intervention Study 2016 West ISD. Gillian Ritchie Clinical Pharmacist Intervention Study 2016 West ISD Gillian Ritchie Clinical Pharmacist Introduction Annual data collection Two weeks All Medicines Management Team interventions Details recorded Classified by type Outcomes

More information

Nibal R. Chamoun, Pharm.D., BCPS Clinical Assistant Professor of Pharmacy Practice at the Lebanese American University Clinical Pharmacy Coordinator

Nibal R. Chamoun, Pharm.D., BCPS Clinical Assistant Professor of Pharmacy Practice at the Lebanese American University Clinical Pharmacy Coordinator Nibal R. Chamoun, Pharm.D., BCPS Clinical Assistant Professor of Pharmacy Practice at the Lebanese American University Clinical Pharmacy Coordinator at LAUMCRH Review the mechanism of action, indications

More information

Policy: Created: 2/11/2015; Approved: Adult Pharmacokinetic Dosing and Monitoring- Vancomycin Dosing

Policy: Created: 2/11/2015; Approved: Adult Pharmacokinetic Dosing and Monitoring- Vancomycin Dosing ProMedica Health System Clinical Interdepartmental Policy and Procedure: Section: Policy: Date: Subject: Pharmacy Created: 2/11/2015; Approved: Adult Pharmacokinetic Dosing and Monitoring- Vancomycin Dosing

More information

Reducing Falls Causing Harm in Older People with Dementia. Professor Tony Elliott South Staffordshire and Shropshire FT

Reducing Falls Causing Harm in Older People with Dementia. Professor Tony Elliott South Staffordshire and Shropshire FT Reducing Falls Causing Harm in Older People with Dementia Professor Tony Elliott South Staffordshire and Shropshire FT Project Site 16 bedded Dementia Inpatient Unit Acute admissions from home, DGHs or

More information

Enhanced Recovery after Surgery

Enhanced Recovery after Surgery Enhanced Recovery after Surgery AKA ERAS What is Enhanced Recovery (ER)? Paradigm shift in surgery and surgical care of the patient Philosophy of care Perioperative continuum Multidisciplinary Patient

More information

Xarelto rivaroxaban Prescriber Guide

Xarelto rivaroxaban Prescriber Guide Xarelto rivaroxaban Prescriber Guide Patient Alert Card A patient alert card must be provided to each patient who is prescribed Xarelto 2.5 mg, 10 mg, 15 mg or 20 mg and is provided with the product package.

More information

Practical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease

Practical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease Practical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease Cyrille K. Cornelio, Pharm.D. PGY2 Cardiology Pharmacy Resident The University of Oklahoma College of Pharmacy

More information

BMS Project ID: 432US /16

BMS Project ID: 432US /16 The Bristol-Myers Squibb/Pfizer Medical Alliance would like to inform you that the following sections of the prescribing information for ELIQUIS (apixaban) have been updated and the underlined text denotes

More information

Venous Thromboembolism Prophylaxis: Checked!

Venous Thromboembolism Prophylaxis: Checked! Venous Thromboembolism Prophylaxis: Checked! William Geerts, MD, FRCPC Director, Thromboembolism Program, Sunnybrook HSC Professor of Medicine, University of Toronto National Lead, VTE Prevention, Safer

More information

IMPROVING VANCOMYCIN DOSING AND MONITORING IN THE ABSENCE OF A FORMAL PHARMACOKINETIC SERVICE:

IMPROVING VANCOMYCIN DOSING AND MONITORING IN THE ABSENCE OF A FORMAL PHARMACOKINETIC SERVICE: IMPROVING VANCOMYCIN DOSING AND MONITORING IN THE ABSENCE OF A FORMAL PHARMACOKINETIC SERVICE: IMPACT OF A PHARMACY DEPARTMENT-WIDE APPROACH IN A COMMUNITY HOSPITAL SETTING November 2014 Monica Dorobisz,

More information

Standardizing Detection of Acute Kidney Injury in an Integrated Delivery Health System

Standardizing Detection of Acute Kidney Injury in an Integrated Delivery Health System Standardizing Detection of Acute Kidney Injury in an Integrated Delivery Health System Tarush Kothari, MD, MPH Physician Informaticist, Northwell Health Laboratories Assistant Professor in Pathology and

More information

Cincinnati Children s Hospital Medical Center PHO/OVPCA Constipation Initiative Monthly Report February 2018

Cincinnati Children s Hospital Medical Center PHO/OVPCA Constipation Initiative Monthly Report February 2018 Cincinnati Children s Hospital Medical Center PHO/OVPCA Constipation Initiative Monthly Report February 2018 Aim: Project focus to embed evidence based protocol for the treatment of Constipation in the

More information

HEPARIN-INDUCED THROMBOCYTOPENIA (HIT)

HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) OBJECTIVE: To assist clinicians with the investigation and management of suspected and documented heparin-induced thrombocytopenia (HIT). BACKGROUND: HIT is a transient,

More information

Clinical Safety & Effectiveness Cohort # 10

Clinical Safety & Effectiveness Cohort # 10 1 Clinical Safety & Effectiveness Cohort # 10 Improving Weight-Based Vancomycin Dosing and Monitoring DATE Educating for Quality Improvement & Patient Safety 2 Financial Disclosure lizabeth A. Walter,

More information

Index. Note: Page numbers of article titles are in boldface type.

Index. Note: Page numbers of article titles are in boldface type. Note: Page numbers of article titles are in boldface type. A Absorption of drugs in the elderly, 278 Abuse substance in patient with cognitive impairment safety concerns related to, 323, 325, 329 330 ADEs.

More information

Counties in the top and bottom two quintiles of both diabetes and obesity, Age-adjusted percentage of adults aged 20 years who are obese, 2007

Counties in the top and bottom two quintiles of both diabetes and obesity, Age-adjusted percentage of adults aged 20 years who are obese, 2007 Impact of Obesity on Medication Dosing John C. Williamson, PharmD, BCPS, AAHIVE Wake Forest University Baptist Medical Center Winston-Salem, NC Objectives Determine what constitutes the various forms of

More information

30 mg single intravenous bolus plus a 1 mg/kg subcutaneous dose followed by 1 mg/kg subcutaneously every 12 hours

30 mg single intravenous bolus plus a 1 mg/kg subcutaneous dose followed by 1 mg/kg subcutaneously every 12 hours HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use safely and effectively. See full prescribing information for. (enoxaparin sodium injection), for

More information

Prostate Biopsy Alerts

Prostate Biopsy Alerts Prostate Biopsy Alerts Saskatchewan Prostate Assessment Pathway Guidelines for the Primary Care Provider for Patient Preparation and the Management of Medications and Complications September 2016 Table

More information

Clinical Guideline for Anticoagulation in VTE

Clinical Guideline for Anticoagulation in VTE Clinical Guideline for Anticoagulation in VTE These clinical guidelines are intended to provide evidence-based recommendations regarding the anticoagulation in patients with DVT and PE. Please note that

More information

North Dakota Board of Pharmacy

North Dakota Board of Pharmacy North Dakota Board of Pharmacy Updates on Drug Abuse Trends, the PDMP and Medical Marijuana Mark J. Hardy, Pharm D Executive Director Disclosure Statement I have no conflict of interests to report Objectives

More information

Perioperative Management of Anticoagulation

Perioperative Management of Anticoagulation Perioperative Management of Anticoagulation Presented By: Nibal R. Chamoun, PharmD, BCPS Clinical Assistant Professor, Clinical Coordinator Lebanese American University, School of Pharmacy Presented at:

More information

Inpatient Delirium Management: A Quality Improvement Project for Hospitalized Veterans. IIndiana Nursing Summit

Inpatient Delirium Management: A Quality Improvement Project for Hospitalized Veterans. IIndiana Nursing Summit Inpatient Delirium Management: A Quality Improvement Project for Hospitalized Veterans IIndiana Nursing Summit November 5, 2018 At the conclusion of this presentation, participants will be able to: Identify

More information

Inpatient Delirium Management: A Quality Improvement Project for Hospitalized Veterans

Inpatient Delirium Management: A Quality Improvement Project for Hospitalized Veterans Inpatient Delirium Management: A Quality Improvement Project for Hospitalized Veterans IIndiana Nursing Summit November 5, 2018 Veteran Health Indiana At the conclusion of this presentation, participants

More information

to a DOAC anticoagulants (DOACs) dosing of DOACs for various indications switching from a DOAC and switching

to a DOAC anticoagulants (DOACs) dosing of DOACs for various indications switching from a DOAC and switching Linda Kelly, PharmD, PhC, CACP Presbyterian Healthcare Services } Identify the FDA approved direct oral anticoagulants (DOACs) } Distinguish the differences in the dosing of DOACs for various indications

More information

ADULT TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR) TELEMETRY BED TRANSFER ORDERS 1 of 4

ADULT TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR) TELEMETRY BED TRANSFER ORDERS 1 of 4 TELEMETRY BED TRANSFER 1 of 4 9 Actual 9 Estimated Patient ID Area Weight kg 9 Actual 9 Estimated Height cm ALLERGIES: REFER TO ALLERGY PROFILE/ POWERCHART Transfer to: 10 South Attending Physician: Diagnosis:

More information

ADMINISTRATIVE CLINICAL Page 1 of 6

ADMINISTRATIVE CLINICAL Page 1 of 6 ADMINISTRATIVE CLINICAL Page 1 of 6 Anticoagulant Guidelines #2: REVERSAL OF OR MANAGEMENT OF BLEEDING WITH ANTICOAGULANTS Origination Date: Revision Date: Reviewed Date: 09/12 09/12, 01/13, 11/13, 11/15

More information

4/24/15. New Mexico s Prescription Monitoring Program. Carl Flansbaum, RPh. PMP Director New Mexico Board of Pharmacy. New Mexico and the PMP

4/24/15. New Mexico s Prescription Monitoring Program. Carl Flansbaum, RPh. PMP Director New Mexico Board of Pharmacy. New Mexico and the PMP New Mexico s Carl Flansbaum, RPh. PMP Director New Mexico Board of Pharmacy New Mexico and the PMP In 2012, New Mexico had the 3 nd Highest Overdose Death Rate in Nation.! 492 Deaths or a rate of 23.6

More information

Change from lovenox to pradaxa

Change from lovenox to pradaxa P ford residence southampton, ny Change from lovenox to pradaxa 14-11-2017 We wanted to put out a friendly reminder that the Ask 3 Teach 3 (A3T3) initiative is indeed full swing. This is an multidisciplinary

More information

FRAGMIN (dalteparin sodium injection) for Subcutaneous Use Only Initial U.S. Approval: 1994

FRAGMIN (dalteparin sodium injection) for Subcutaneous Use Only Initial U.S. Approval: 1994 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use FRAGMIN safely and effectively. See full prescribing information for FRAGMIN. FRAGMIN (dalteparin

More information

Pain Management and Safe use of opioids in hospitals. Kyoung-Sil Kang, PharmD, BCPS Scott Tam, PharmD Lauve Casimir, RN, MSN

Pain Management and Safe use of opioids in hospitals. Kyoung-Sil Kang, PharmD, BCPS Scott Tam, PharmD Lauve Casimir, RN, MSN Pain Management and Safe use of opioids in hospitals Kyoung-Sil Kang, PharmD, BCPS Scott Tam, PharmD Lauve Casimir, RN, MSN Bronx Care Health System Bronx Lebanon Hospital Concourse/ Fulton division, Nursing

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Single Technology Appraisal (STA)

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Single Technology Appraisal (STA) Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective on the technology

More information

McLean ebasis plus TM

McLean ebasis plus TM McLean ebasis plus TM Sample Hospital (0000) Report For Qtr HBIPS Core Measures McLean Hospital 115 Mill Street Belmont, MA 02478 1 2012 Department of Mental Health Services Evaluation Tel: 617-855-3797

More information

Incorporated Dosing Guidelines: Intravenous Heparin Therapy Initial Dose

Incorporated Dosing Guidelines: Intravenous Heparin Therapy Initial Dose Intravenous Heparin Therapy Initial Dose (Max Dose) IV Infusion Rate IV Infusion Rate (Max Dose) Lab Tests High Dose 80 units/kg 8,000 units 18 units/kg/hr 1,800 units/hr Intermediate Dose 5,000 units

More information

New Age Anticoagulants: Bleeding Considerations

New Age Anticoagulants: Bleeding Considerations Ontario Regional Blood Coordinating Network March 23, 2012 New Age Anticoagulants: Bleeding Considerations Bill Geerts, MD, FRCPC Thromboembolism Specialist, Sunnybrook HSC Professor of Medicine, University

More information

Update on Oral Anticoagulants. Dr. Miten R. Patel Cancer Specialists of North Florida Cell

Update on Oral Anticoagulants. Dr. Miten R. Patel Cancer Specialists of North Florida Cell Update on Oral Anticoagulants Dr. Miten R. Patel Cancer Specialists of North Florida Cell 904-451-9820 Email miten.patel@csnf.us Overview Highlights of the 4 new approved oral anticoagulants Results from

More information

INDICATIONS FOR THROMBO-PROPHYLAXIS AND WHEN TO STOP ANTICOAGULATION BEFORE ELECTIVE SURGERY

INDICATIONS FOR THROMBO-PROPHYLAXIS AND WHEN TO STOP ANTICOAGULATION BEFORE ELECTIVE SURGERY INDICATIONS FOR THROMBO-PROPHYLAXIS AND WHEN TO STOP ANTICOAGULATION BEFORE ELECTIVE SURGERY N.E. Pearce INTRODUCTION Preventable death Cause of morbidity and mortality Risk factors Pulmonary embolism

More information

Anticoagulation Therapy in LTC

Anticoagulation Therapy in LTC Anticoagulation Therapy in LTC By: Cynthia Leung, RPh, BScPhm, PharmD. Clinical Consultant Pharmacist MediSystem Pharmacy Jun 11, 2013 Agenda Stroke and Bleeding Risk Assessment Review of Oral Anticoagulation

More information

East London Community Kidney Service

East London Community Kidney Service East London Community Kidney Service Sally Hull, Neil Ashman, Sec Hoong, Nicola Thomas, Helen Rainey April 2017 Haemodialysis/million population What is the Problem? Fast rising ESRD rates in East London

More information

Reducing COPD Exacerbation Readmissions in a Community-Based Teaching Hospital

Reducing COPD Exacerbation Readmissions in a Community-Based Teaching Hospital Reducing COPD Exacerbation Readmissions in a Community-Based Teaching Hospital Dawn Waddell, PharmD, BCPS Clinical Pharmacy Manager Lisa Kingdon, PharmD, BCPS Clinical Pharmacy Specialist Dawn Waddell

More information

Direct Oral Anticoagulant Use in Older Adults Brian Skinner, PharmD

Direct Oral Anticoagulant Use in Older Adults Brian Skinner, PharmD Direct Oral Anticoagulant Use in Older Adults Brian Skinner, PharmD Dr. Skinner serves as an Assistant Professor of Pharmacy Practice at Manchester University, and he is one of three Internal Medicine

More information

Potential disruption from private exchanges and narrow networks. In 2011, less than 10% of companies used High Performing Networks (narrow networks)

Potential disruption from private exchanges and narrow networks. In 2011, less than 10% of companies used High Performing Networks (narrow networks) 1 3 2 Potential disruption from private exchanges and narrow networks. In 2011, less than 10% of companies used High Performing Networks (narrow networks) and in 2014 estimated to be 40%. By 2018, that

More information

Urinary Catheters Do Not Have to Be Removed if They Were Never Placed

Urinary Catheters Do Not Have to Be Removed if They Were Never Placed Urinary Catheters Do Not Have to Be Removed if They Were Never Placed A formal performance improvement project to decrease utilization of urinary catheters in surgical patients A. D. Yang 1,2,3, M. W.

More information

A Review of Direct-Acting Oral Anticoagulants (DOACs) and Their Use in Special Populations

A Review of Direct-Acting Oral Anticoagulants (DOACs) and Their Use in Special Populations A Review of Direct-Acting Oral Anticoagulants (DOACs) and Their Use in Special Populations Allison Bernard, PharmD PGY2 Ambulatory Care Resident University of Iowa Hospitals and Clinics October 25 th,

More information

Disclosures. Learning Objectives 4/26/2017

Disclosures. Learning Objectives 4/26/2017 Implementation of a quality improvement initiative to ensure the safe transition from prior-to-admission concentrated insulins to a formulary insulin regimen ERICA J. RHEIN, PHARMD PGY1 PHARMACY PRACTICE

More information

venous thromboembolism

venous thromboembolism Venous thromboembolism reduction initiative: A multifaceted collaborative effort to protect Intermountain Healthcare patients from hospitalassociated venous thromboembolism (HA-VTE) 14 th Annual Research

More information

Oral Anticoagulation Drug Class Prior Authorization Protocol

Oral Anticoagulation Drug Class Prior Authorization Protocol Oral Anticoagulation Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review

More information

Disclosures. Overview. Have you ever. The Perioperative Management of Anticoagulants. No financial conflicts of interest to disclose

Disclosures. Overview. Have you ever. The Perioperative Management of Anticoagulants. No financial conflicts of interest to disclose Disclosures No financial conflicts of interest to disclose The Perioperative Management of Anticoagulants Margaret C. Fang, MD, MPH Associate Professor of Medicine UCSF Division of Hospital Medicine Medical

More information

ADVERSE REACTIONS Most common adverse reaction (incidence > 5%) is bleeding. (6.1)

ADVERSE REACTIONS Most common adverse reaction (incidence > 5%) is bleeding. (6.1) HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use BEVYXXA safely and effectively. See full prescribing information for BEVYXXA. BEVYXXA (betrixaban)

More information

Statit pimd Client Panel. Guy March, Product Lead, Midas+ Statit

Statit pimd Client Panel. Guy March, Product Lead, Midas+ Statit Statit pimd Client Panel Guy March, Product Lead, Midas+ Statit Statit pimd/ppr Statit Software Started ~25 years ago Currently serving 650 hospitals Guy March Working with Statit QC products for over

More information

Misunderstandings of Venous thromboembolism prophylaxis

Misunderstandings of Venous thromboembolism prophylaxis Misunderstandings of Venous thromboembolism prophylaxis Veerendra Chadachan Senior Consultant Dept of General Medicine (Vascular Medicine and Hypertension) Tan Tock Seng Hospital, Singapore Case scenario

More information

DVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE)

DVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE) DVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE) Introduction VTE (DVT/PE) is an important complication in hospitalized patients Hospitalization for acute medical illness

More information

A Paradigm Shift for Extended VTE Thromboprophylaxis in Hospitalized, Nonsurgical, Acutely Ill Patients

A Paradigm Shift for Extended VTE Thromboprophylaxis in Hospitalized, Nonsurgical, Acutely Ill Patients You are cordially invited to attend a peer-to-peer presentation A Paradigm Shift for Extended VTE Thromboprophylaxis in Hospitalized, Nonsurgical, Acutely Ill Patients Presented by: Hosted by: Program

More information

PRODUCT MONOGRAPH. (Enoxaparin sodium solution for injection, manufacturer s standard) 150 mg/ml. 120 mg/0.8 ml

PRODUCT MONOGRAPH. (Enoxaparin sodium solution for injection, manufacturer s standard) 150 mg/ml. 120 mg/0.8 ml PRODUCT MONOGRAPH Pr LOVENOX (Enoxaparin sodium solution for injection, manufacturer s standard) 100 mg/ml 30 mg/0.3 ml 40 mg/0.4 ml 60 mg/0.6 ml 80 mg/0.8 ml 100 mg/ml 300 mg/3 ml Pr LOVENOX HP (Enoxaparin

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Single Technology Appraisal (STA)

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Single Technology Appraisal (STA) Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective on the technology

More information

TRANSFORMING STROKE CARE IN THE CAPITAL: THE LONDON STROKE STRATEGY

TRANSFORMING STROKE CARE IN THE CAPITAL: THE LONDON STROKE STRATEGY TRANSFORMING STROKE CARE IN THE CAPITAL: THE LONDON STROKE STRATEGY LUCY GROTHIER Director South London Cardiac and Stroke Network lucy.grothier@slcsn.nhs.uk 27 th May 2011 Gaps in London stroke care GAPS

More information

These are guidelines only and can be deviated from if it is thought to be in the patient s best interest.

These are guidelines only and can be deviated from if it is thought to be in the patient s best interest. Clinical Guideline Venothromboembolism prophylaxis: Trauma and Orthopaedics Venous thromboembolism (VTE) is a recognised complication associated with inactivity and surgical procedures. Therefore, all

More information

Novel Anticoagulant Drugs. by: Dr. M. Kamandi Fellowship of hematology and Oncology

Novel Anticoagulant Drugs. by: Dr. M. Kamandi Fellowship of hematology and Oncology Novel Anticoagulant Drugs by: Dr. M. Kamandi Fellowship of hematology and Oncology A-Novel Oral Anticoagulants A drug that is: safe and effective has predictable pharmacology has few drug drug and drug

More information

Antiplatelet and Anticoagulant Therapy Management Surrounding Regional Anesthesia

Antiplatelet and Anticoagulant Therapy Management Surrounding Regional Anesthesia 1 Antiplatelet and Anticoagulant Therapy Management Surrounding Regional Anesthesia Key Points: Neuraxial complications are extremely rare. Epidural hematomas are one possible complication of neuraxial

More information

Prevention of Venous Thromboembolism

Prevention of Venous Thromboembolism Prevention of Venous Thromboembolism Surgical Care Improvement Project Dale W. Bratzler, DO, MPH President and CEO Dale W. Bratzler, DO, MPH Oklahoma Foundation for Medical Quality QIOSC Medical Director

More information

DOAC the story so far... Dr GM Benson Director NI Haemophilia and Thrombosis Centre BHSCT

DOAC the story so far... Dr GM Benson Director NI Haemophilia and Thrombosis Centre BHSCT DOAC the story so far... Dr GM Benson Director NI Haemophilia and Thrombosis Centre BHSCT A rose by any other name.. Recommendation on the nomenclature for oral anticoagulants: communication from the SSC

More information

Monitoring EHRs to Ensure Safe and Effective Use: An Overview of What is Required. Dean F. Sittig, PhD

Monitoring EHRs to Ensure Safe and Effective Use: An Overview of What is Required. Dean F. Sittig, PhD Monitoring EHRs to Ensure Safe and Effective Use: An Overview of What is Required Dean F. Sittig, PhD ARRA increases pressure on practitioners to implement EHRs Research and experience on EHR implementation

More information